Immune checkpoint blockade has achieved significant therapeutic success for a subset of cancer patients; however, a large portion of cancer patients do not respond. Unresponsive tumors are characterized as being immunologically "cold," indicating that these tumors lack tumor antigen-specific primed cytotoxic T cells. Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MerTK) and split tyrosine-kinase domaincontaining receptors (VEGFR and PDGFR families and KIT) plus RET and MET, targets that contribute to the immunosuppressive tumor microenvironment. We report that sitravatinib has potent antitumor activity by targeting the tumor microenvironment, resulting in innate and adaptive immune cell changes that augment immune checkpoint blockade. These results suggest that sitravatinib has the potential to combat resistance to immune checkpoint blockade and expand the number of cancer patients that are responsive to immune therapy.
Introduction
Immune checkpoint (e.g., PD-L1/PD-1 or CTLA-4) inhibition has provided significant improvement for the treatment of many cancer types (1, 2) . However, multiple features of the tumor microenvironment contribute to the efficacy of immune checkpoint blockade, and a large portion of cancer patients remain refractory to this important new treatment modality (3) . Response to immune checkpoint blockade, especially targeting the PD-1 axis, requires a functional cancer immunity cycle that results in primed tumor antigen-specific effector T cells (4) . There are multiple roadblocks in the tumor microenvironment that hinder the development of such effector T cells. A major hurdle is the function of immune-suppressive myeloid and lymphoid cells in tumors. These cells, including myeloid-derived suppressor cells (MDSCs), immune-suppressive macrophages, Tregs, and immature DCs, express multiple cell surface receptors that stimulate their recruitment into the tumor microenvironment and promote the production of immune-suppressive cytokines.
TAM (TYRO3, AXL, MerTK) receptors and other receptor tyrosine kinases containing a split tyrosine-kinase domain, such as VEGFR and PDGFR family members and KIT, are key signaling nodes that contribute to the immune-suppressive microenvironment of many tumors (5) (6) (7) (8) (9) (10) . For example, AXL and MerTK are expressed on immune cells, including DCs, MDSCs, and macrophages (5) . The activation of TAM receptors by their ligands Gas6 and protein S in the tumor microenvironment, especially MerTK, suppresses the expression of proinflammatory cytokines and stimulates immunosuppressive cytokine production. Moreover, MerTK is also a potent direct suppressor of T cell responses (11) . Split tyrosine-kinase domain-containing receptors promote proliferation of immunosuppressive cells, limit T cell infiltration into tumors, and promote T cell exhaustion (6, 12) . Additionally, PDGF receptors can inhibit the maturation of DCs and induce Tregs (13) . Given the proposed contribution of TAM receptors and split tyrosine-kinase domain-containing receptors to the immune landscape of tumors, we investigated the use of sitravatinib and glesatinib, which are spectrum-selective tyrosine kinase inhibitors that target TAM receptors and multiple split tyrosine-kinase domain-containing receptors.
Sitravatinib is currently under clinical testing for multiple indications, with 4 ongoing clinical studies (Clinicaltrials.gov, NCT02978859, NCT02219711, NCT02954991, and NCT03015740). A phase II clinical study in checkpoint blockade for refractory non-small cell lung cancer has provided evidence that sitravatinib can restore response to anti-PD-1 (nivolumab) with an acceptable toxicity profile (14) . These results
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highlight the potential immune-activating effects of sitravatinib. We sought to investigate the induction of immune activity by sitravatinib and glesatinib in syngeneic murine cancer models. We found that inhibition of TAM receptor activation by the compounds reduces expression of markers associated with immune suppression in macrophages in a MerTK-dependent manner. Additionally, sitravatinib and glesatinib showed potent single-agent antitumor efficacy and enhanced the activity of PD-1 blockade through promoting an antitumor immune microenvironment.
Results
MerTK inhibition with sitravatinib directly affects macrophage phenotype. Since sitravatinib potently inhibits TAM receptors, which are important in mediating an immunosuppressive macrophage phenotype (5), we investigated the effect of sitravatinib on cytokine-stimulated polarization of primary bone marrow-derived macrophages (BMDMs). We found that sitravatinib inhibited the expression of Arg1 stimulated by IL-4 and the expression of Il-6 and Il-12 induced by LPS treatment (Figure 1 ). To better mimic the cytokine milieu found in tumors, we stimulated BMDMs with LPS ( Figure 1A ) or IL-4 ( Figure 1B ) in the presence of conditioned media (CM) from murine lung cancer (KLN205) cells. Treatment with sitravatinib dose-dependently inhibited the IL-4 plus CM-mediated expression of Arg1, Ym-1, and Fizz1, markers associated with an immunosuppressive macrophage phenotype, but did not affect the LPS plus CM-induced expression of Tnfα, Il-6, or Il-12, markers of an immunostimulatory macrophage phenotype (15) . These data suggest that sitravatinib can prevent monocytes from polarizing into immunosuppressive macrophages in the presence of potent immune-suppressive signals. The data also demonstrate that sitravatinib did not abrogate the induction of an immunostimulatory macrophage phenotype. Similar results were obtained with Three independent experiments using duplicate samples were performed. Data are displayed as fold change normalized to control in each condition (mean ± SD). For each marker, the top graph is the basal expression change in each stimulation condition, and the bottom graph is expression change caused by different concentrations of sitravatinib in each condition. *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 vs. the control (WT macrophages without stimulation) or DMSO (0 nM) in each condition by ANOVA. ) animals were subjected to the experimental conditions described above. MerTK -/-BMDMs were unaffected by sitravatinib or glesatinib, indicating that MerTK is critical to the effect of the compounds on macrophage polarization ( Figure 1 and Supplemental Figure  1 , A and B). These data also suggest that the presence of Gas6 or protein S is important in regulation of macrophage phenotype.
Sitravatinib has potent antitumor activity in vivo. To determine the single-agent antitumor efficacy of sitravatinib, we administered the compound to immunocompetent mice bearing KLN205, CT1B-A5, or E0771 tumors (Figure 2 , A-C). In each model, sitravatinib significantly inhibited tumor progression and induced tumor regression. Glesatinib also showed single-agent activity in each tumor model (Supplemental Figure  2 , A-C). We observed no adverse effects of the compounds but noted that treatment with sitravatinib or glesatinib reduced tumor-induced splenomegaly, suggestive of immune modulatory activity.
To demonstrate the effect of the compounds on tumor cell viability, we performed in vitro colony-forming and MTS viability assays. Each compound reduced colony formation in a dose-dependent manner (Figure 2D and Supplemental Figure 2D ) and inhibited tumor cell viability with an IC 50 of approximately 1 μM ( Figure 2E and Supplemental Figure 2E ), a concentration considerably higher than the predicted plasma concentration of sitravatinib (10 nM) after dosing at 20 mg/kg (Supplemental Table 1 ). These data suggest that the potent antitumor activity observed was unlikely due solely to direct tumor cell killing but related to microenvironmental changes induced by sitravatinib.
To determine the effect of the compounds on MerTK activity in vivo, we probed lysates from treated KLN205 tumors for active MerTK and found that both compounds suppressed MerTK phosphorylation ( Figure 3A ; see complete unedited blots in the supplemental material), with sitravatinib showing a stronger effect. Histologic analysis of KLN205 tumors demonstrated that sitravatinib-treated tumors KLN205 cells (A, n = 11/group) subcutaneously into 6-week-old DBA/2 mice, 1 × 10 6 CT1B-A5 cells (B, n = 5/group) subcutaneously into 6-week-old C57BL/6 mice, and 0.5 × 10 6 E0771 cells (C, n = 5/ group) orthotopically into the mammary fat pads of 6-week-old female C57BL/6 mice. Mice with established tumors (500-700 mm 3 ) were treated with control (Ctrl, vehicle, once per day) or sitravatinib (sitrav, p.o. 20 mg/kg, once per day). Effects on tumor growth are shown after 6 days of treatment. Tumor and spleen weight were determined in each mouse (mean ± SD). *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001 vs. control by t test. (D) Colony formation for KLN205 and E0771 cell lines grown in normal growth performed with or without sitravatinib at the indicated doses for 14 days. Two independent experiments using triplicate samples were performed. Mean ± SD colonies/hpf are shown. (E) Cell growth assays were performed in a 96-well format for 5 days using MTS. Three independent experiments using two 96-well plates/cell line were performed. Drug-sensitivity curves are displayed.
showed increased necrosis, elevated cleaved caspase-3 (CC3), decreased Ki67 expression, and reduced microvessel density (CD31), while tumor cell death induced by glesatinib was less substantial and it did not reduce microvessel density ( Figure 3B ). These results suggest both compounds target critical pathways in the tumor microenvironment that support tumor progression.
Sitravatinib alters the immune landscape of KLN205 tumors to favor immune checkpoint blockade. Given the potent antitumor activity of sitravatinib and the fact that TAM receptors contribute to the immune microenvironment in tumors, we performed gene expression analysis (NanoString Technologies) using tumor tissue collected from mice bearing KLN205 tumors treated with control, glesatinib, or sitravatinib. Compared with those treated with glesatinib, we found that sitravatinib-treated tumors had more significant gene set changes. Multiple genes associated with angiogenesis were among the most downregulated in sitravatinib-treated tumors, consistent with its blockade of VEGFR family RTKs, while inflammatory genes were among the highest upregulated in treated tumors (Figure 4, A and B) . Interestingly, the expression of Pd-l1 (Cd274) was elevated by glesatinib and sitravatinib, suggesting that the compounds may enhance response to immune checkpoint blockade (16) . This is supported by analysis of gene program/pathways that were altered by sitravatinib, which included multiple pathways associated with innate and adaptive immune response ( Figure 4C ).
To further investigate the effect of sitravatinib on the immune landscape of KLN205 tumors, flow cytometry was performed on tumors and spleens from mice treated for 6 days ( Figure 5 ). Sitravatinib significantly Original magnification, ×20. **P < 0.01, ****P < 0.001 vs. control by ANOVA.
reduced the number of tumor-associated immunosuppressive myeloid cells, including monocytic MDSCs and M2 macrophages. Sitravatinib also increased the number of CD4 + T cells and exhausted CD8 + T cells characterized by PD-1 and CTLA-4 expression. In comparison, we found that spleens from sitravatinib-treated mice had an increase in CD4 + T cells and proliferating CD8 + T cells. The immune cell changes in the tumors and the spleen suggested that sitravatinib might enhance the effect of PD-1 blockade. Although glesatinib had similar trends (Supplemental Figure 3, A-C) , the immune cell changes were not as significant as seen with sitravatinib. These results might be explained by the less potent activity of glesatinib against MerTK or through contribution of other distinct sitravatinib RTK targets.
Sitravatinib enhances the efficacy of PD-1 blockade. To test the combinatorial effect of sitravatinib and PD-1 blockade, we treated cohorts of KLN205 or E0771 tumor-bearing mice with the compound with or without anti-PD-1. Mice were treated for 2.5 weeks in each model. Sitravatinib significantly enhanced the efficacy of PD-1 blockade ( Figure 6, A and B) . Glesatinib treatment also enhanced the efficacy of anti-PD-1 therapy (Supplemental Figure 4 , A and B) but was less potent that sitravatinib. In fact, 2 of 14 mice bearing E0771 tumors treated with anti-PD-1 plus sitravatinib showed complete remission and stayed tumor free for 50 days. To test whether these 2 animals developed an adaptive antitumor response with immune memory, we rechallenged the animals by implanting E0771 cells in the mammary fat pad (on the opposite side from the original injection). Control mice were also implanted with E0771 cells and showed robust and predictable tumor formation and growth. However, the 2 animals that showed complete response to sitravatinib and anti-PD-1 failed to grow E0771 tumors upon rechallenge ( Figure 6C ).
Discussion
Our study has found that sitravatinib and glesatinib have potent single-agent antitumor activity; moreover, sitravatinib can alter the immune landscape of tumors to favor immune checkpoint blockade. In 3 different preclinical tumor models, including KLN205, an aggressive lung cancer model that is resistant to checkpoint blockade, the tumor response to sitravatinib and glesatinib was rapid and consistent ( Figure 2 , A-C, and Supplemental Figure 2, A-C) . Consistently, sitravatinib was also found to have potent antitumor activity in preclinical models of sarcoma (17) . RNA was isolated from KLN205 tumors treated for 6 days with sitravatinib (sitra) or glesatinib (gles) and was analyzed using a preassembled nCounter PanCancer Immune Profiling Panel (mouse) and the nCounter system (NanoString Technologies). Samples were then normalized based on the geometric means of the supplied positive controls and the panel of housekeeping genes, as recommended by the manufacturer. Only genes that were significantly different (P < 0.05; t test, false discover rate adjusted) and at least 1.5-fold differentially expressed between groups were considered. The most downregulated (A) and upregulated genes (B) from the gene expression analysis (NanoString Technologies) were displayed (mean ± SD). (C) Upregulated and downregulated gene program/pathways.
Our in vitro studies demonstrate that each compound has direct antitumor cell effects, albeit at markedly higher concentrations than required for in vivo efficacy. The major targets of each compound are pathways associated with microenvironmental features of tumors, and the predicted in vivo concentration of the compounds is substantially below the observed in vitro IC 50 values. We therefore propose that the potent antitumor activity of each compound is largely due to the effect of sitravatinib and glesatinib on the tumor microenvironment. Therapies against some of these targets, for example, angiogenesis, have been explored for decades with limited success in solid tumors (18) . A major unmet challenge with the use of targeted therapeutic agents is the propensity of tumor cells to activate alternative pathways that lead to therapeutic resistance. Sitravatinib and glesatinib have a relatively broad spectrum of targets that are inhibited at pharmacologically achievable doses. It is possible that inhibition of multiple aspects of the tumor microenvironment reduces the chance of resistance-derived inhibition of a single but important biologic process.
What may distinguish sitravatinib and glesatinib relative to other multireceptor tyrosine kinases is their activity against the TAM receptors. Of the multireceptor tyrosine kinase inhibitors in active clinical development, sitravatinib and glesatinib are arguably the most effective TAM receptor inhibitors currently available. We propose that the inhibition of TAM receptors enables the compounds to alter the immune landscape. This is the first report to our knowledge of the effect of sitravatinib and glesatinib on the immunosuppressive tumor microenvironment, as evidenced in vitro by observations using primary BMDMs, in vivo through gene expression and flow cytometry, and functionally through the potentiation of immune checkpoint blockade. Since resistance to immune therapy remains an unmet challenge in the treatment of many cancers, these compounds may offer therapeutic benefit that improves response to immune checkpoint blockade. 
Methods
Cell lines. KLN205, a murine lung cancer cell line, was obtained from ATCC (CRL-1453), and E0771, a murine breast cancer cell line, was a gift from Philip Thorpe (University of Texas Southwestern Medical Center). CT1B-A5, an isogenic pancreatic cancer cell line, was derived from KPfC (Kras
LSL-G12D
; Trp53 fl/fl ; PDX Cre/+ ) mice. Cells were cultured in DMEM (Invitrogen) or RPMI (Invitrogen) containing 5% FBS and maintained at 37°C in a humidified incubator with 5% CO 2 and 95% air and confirmed to be pathogen free before use.
Animal studies. KLN205 cells (0.5 × 10 6 ) were injected subcutaneously into 6-week-old DBA/2 mice, CT1B-A5 cells (1 × 10 6 ) were injected subcutaneously into 6-week-old C57BL/6 mice, and E0771 cells (0.5 × 10 6 ) were injected orthotopically into the mammary fat pad of 6-week-old female C57BL/6 mice. Tumor volumes were measured twice weekly using a digital caliper, and volumes were calculated using the formula: V = (a × b 2 )/2, where a is the largest dimension and b is the smallest dimension. For endpoint studies, mice with established tumors (500-700 mm 3 ) were treated with control (vehicle, once per day), sitravatinib (MGCD516, p.o. 20 mg/kg, once per day), glesatinib (MGCD265, p.o. 60 mg/kg, once per day), anti-PD-1 (i.p. 10 mg/kg, every 3 days), or anti-PD-1 in combination with sitravatinib or glesatinib at the indicated doses. Mice were sacrificed after 6 days of therapy, within 6 hours of the final treatment. Tissue was fixed in 10% formalin or snap frozen in liquid nitrogen for further studies or prepared for flow cytometry analysis. For survival studies, mice with a tumor volume of 300 mm 3 (KLN205) or 500 mm 3 (E0771) were selected and allocated into treatment groups defined above. Mice were treated for 2.5 weeks and therapy was withdrawn. Mice were monitored daily for health and sacrificed if they showed signs of morbidity.
Real-time quantitative PCR. BMDMs were harvested from WT C57BL/6 or MerTK -/-mice using standard techniques (19) . To determine if glesatinib and sitravatinib alter the expression of markers of macrophage polarization, BMDMs were stimulated for 2 hours with 20 ng/ml LPS or 18 hours with 40 ng/ ml IL-4, immune stimulatory or immune-suppressive signals, respectively, and different concentrations of 6 KLN205 cells (A) subcutaneously into 6-week-old DBA/2 mice, and 0.5 × 10 6 E0771 cells (B) were injected orthotopically into the mammary fat pads of 6-week-old female C57BL/6 mice. Therapy was initiated in mice with a tumor volume of 300 mm 3 (KLN205) or 500 mm 3 (E0771) and included control (Ctrl, vehicle, once per day), anti-PD-1 (PD-1, i.p. 10 mg/kg, every 3 days), sitravatinib (sitra, p.o. 20 mg/kg, once per day), or anti-PD-1 in combination with sitravatinib at the indicated dose. Mice were treated for 2.5 weeks. **P < 0.01 anti-PD-1 in combination with sitravatinib vs. sitravatinib alone by t test. Two of fourteen mice bearing E0771 tumors treated with the combination therapy showed complete remission and stayed tumor free for 50 days. (C) Rechallenge growth curve of the 2 tumor-free animals from B. We injected 0.5 × 10 6 E0771 cells orthotopically into the mammary fat pads of 6-week-old female C57BL/6 mice (Ctrl, n = 4) and on the contralateral side from the original injection of the 2 tumor-free animals.
